The global recombinant DNA (rDNA) technology market size was estimated at 497.7 billion in 2016. Recombinant DNA technology has offered scientists with unprecedented control over the genetic material. This has extended its usage in widespread applications including conventional as well non-conventional applications. Over the past years, this space has witnessed tremendous achievement in the production of recombinant drugs and therapeutics without the help of human donors.
The classical example of this achievement is commercial success of genetically engineered insulin for diabetes treatment. The biotech and pharmaceutical firms are engaged in deciphering the potential of rDNA techniques in various aspects of disease management. This is mainly to combat with the soaring burden of chronic diseases and keep pace with the growing therapeutics demand.
Germany recombinant DNA technology market, by medical product, 2014 - 2025 (USD Billion)
Furthermore, the gradual evolution of rDNA techniques has drafted new vistas in taking biopharmaceutical development a step ahead by enabling construction of recombinant DNA molecule. Presence of robust biopharmaceuticals pipeline, in particular, recombinant proteins pipeline; is expected to drive the adoption of this technology. Development of recombinant products using rDNA techniques accompanied with CRISPR/Cas9 nuclease, ZFN, and TALEN for easy & precise genome editing with no limitation by organisms is largely responsible for the growth of this space. Dozens of review studies carried out by researchers are evident for the efficiency of rDNA technology.
Growth in Genetically Modified (GM) crop hectarage around the world is a testament to the success of this technology in agriculture and food sector. This has triggered its usage in other non-conventional applications such as development of biofuel and biopesticides to address environmental issues. However, use of this technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and environment, scientific and ethical concerns vary in a discipline-specific manner.
rDNA technology has revolutionized the medical field and is having an ever-increasing impact on clinical medicine. It has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes. Medical segment is further bifurcated into therapeutic agent, recombinant protein, and vaccines. Out of all, therapeutic agents captured dominance over its counterpart segments owing to the presence of a substantial number of genetically engineered products for clinical applications.
However, vaccines are expected to be a source of lucrative revenue generation in the coming years due to the presence of robust vaccine pipeline. Advancements in genetic engineering and process development is anticipated to drive growth in this segment. Non-medical segment of this market is majorly driven by the success of GM crops.
Global hectarage of biotech crops is observed to rise from 110-fold from 1.7 million hectares (1996) to 185.1 million hectares (2016). Top 5 countries that are engaged in planting biotech crops by hectarage are USA, Brazil, Argentina, Canada, and India. Major GM crops are soybean, maize, cotton, and canola. Rise in the penetration of associated technologies such as genome editing in plant tissue engineering is expected to usher progress in this segment.
Expression system and cloning vector are recognized as the two key elements of this technology. Expression systems captured the largest share owing to the ongoing developments for efficient protein expression and for its further isolation on large scale. Majorly used expression systems are mammalian, bacterial, insects, and yeast. Development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed to the significant share of mammalian expression system.
In addition, ongoing research studies to explore the potential of plant as expression system are expected to drive the adoption of plans expression system for GM product development in the coming years. Cloning vectors are recognized as the backbone for production of DNA inserts. In 2016, Cohen was honored with the “2016 Biotechnology Heritage Award” for creating rDNA plasmids. Such achievements are expected to positively influence the growth of this segment throughout the forecast period.
Rapid advances in genetic engineering have played a major role in reshaping the usage of these techniques in health & disease, agriculture, and environment. Health & disease application has accounted for the large share and is expected to maintain its dominance throughout the forecast period. This large share can be attributed to the presence of wide range of recombinant products for human disease treatment such as drugs, vaccine, and enzymes replacements. Moreover, extended use of this technology for animal disease treatment has also driven the progress of this segment.
With growing burden of crop improvement and consequent stress on farmers to meet the customer’s need, this technology has gradually evolved as a panacea for addressing these issues of agriculture sector. This, in turn, has resulted in a notable success of the recombination techniques in food and agriculture application. Other applications, such as biofuel production, are expected to witness considerable growth in the coming years. This is mainly due to ongoing research activities to augment the scope of the space.
Various end-use segment served by this market include pharmaceutical & biotech entities, academic & research institutes, and other industrial entities. Pharmaceutical & biotech firms are major beneficiaries in this market as the techniques accelerate their drug development capabilities. Moreover, the end-products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity. Hence, these organizations account for a larger share.
Moreover, significant capital expenditure taken up by the companies for the development of wide range of recombinant human therapeutics is supportive for the estimated share. These organizations are anticipated to maintain dominance in the coming years as a consequence of rising adoption for biologics production.
Global recombinant DNA technology market size by region, 2016 (%)
The largest share of North America region can be attributed to the fact that a substantial number of biopharmaceutical manufacturing participants are headquartered in the U.S. Moreover, presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven the regional growth. In July 2017, this country witnessed the 1st FDA approval for U.S. gene therapy treatment. The treatment was developed for leukemia, as a result of collaboration between University of Pennsylvania and Novartis Corp. This, in turn, is anticipated to nurture the implementation of rDNA techniques in the region.
Presence of low-cost manufacturing centers in the Asian economies, such as China, have driven significant attention from global entities to translocate their business in this region. Furthermore, Japan is recognized as one of the world’s largest per capita importers of food and feed developed using modern biotechnology tools. Japan’s regulatory system for GE crops continues to improve. Moreover, there is no significant trade barrier in Japan to hamper GE products export from the western countries. As a result, Asia Pacific is expected to emerge as the fastest growing regional market.
Some key participants operating in the space include F. Hoffmann-La Roche Ltd (Genentech, Inc); Profacgen; Amgen Inc; Novartis AG; GenScript; Pfizer Inc; Novo Nordisk A/S; Eli Lilly and Company; Sanofi; Merck & Co., Inc.;Biogen; Biocon; GlaxoSmithKline plc; New England Biolabs.; Cibus; Monsanto Company, and Horizon Discovery Group PLC. These participants are engaged in collaborative alliances to offer their services in various life science domain. Moreover, entities are continuously expanding their manufacturing facilities as a viable strategy to stay competitive in the market space.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Billion and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, UK, China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments covered in the report
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global recombinant DNA technology market on the basis of product, component, application, end-use, and region:
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Component Outlook (Revenue, USD Billion, 2014 - 2025)
Baculovirus / insect
Application Outlook (Revenue, USD Billion, 2014 - 2025)
Food & Agriculture
Health & Disease
End-use Outlook (Revenue, USD Billion, 2014 - 2025)
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.